Option chain shows key data for CervoMed's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for CervoMed.

CervoMed (NASDAQ:CRVO) Stock, Option Chain

CervoMed

CervoMed Inc is a clinical-stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.

Wall Street

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Earnings

Equities

News

Eurozone

Intraday Update

Markets

Trading Ideas

CMRX

CPIX

CRVO

QURE

YEXT

S&amp;P 500 Edges Lower; AutoZone Posts Downbeat Earnings

Turning to Gold

Commodities

OLLI

Gold Gains Over 1%; Ollie&#39;s Bargain Outlet Shares Jump After Q3 Earnings

Genetic,Research,And,Biotech,Science,Concept.,Human,Biology,And,Pharmaceutical

Biotech

Health Care

Movers

General

CervoMed reports RewinD-LB trial results for neflamapimod in dementia with Lewy bodies, highlighting missed endpoints and upcoming data timelines.

CervoMed&#39;s Dementia Candidate Fails In Mid-Stage Study, Stock Plummets

CervoMed Inc

Tembo operates across international markets, including Asia, the Middle East, Africa, Oceania, Europe and North America&nbsp;
Increasing adoption of digital assets and currencies across these markets enables Tembo to provide these payment options, with potential benefits to its working capital cycle
LONDON, Jan. 31, 2025 (GLOBE NEWSWIRE) -- VivoPower International PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VVPR#NASDAQ">VVPR</a>) ("VivoPower" or the "Company") announced today that its subsidiary, Tembo e-LV will commence accepting payments for deposits and orders in Bitcoin (BTC), Ripple (XRP), and Dogecoin (DOGE).

$BTC

$DOGE

$XRP

VVPR

VivoPower's Tembo To Accept Bitcoin, Ripple, And Dogecoin For Payments From Customers And Partners

Macro Economic Events

Economics

Canada PM Trudeau Says If Trump Does Choose To Implement Any Tariffs Against Canada, We're Ready With A Response, Says Any Canadian Response To Tariffs Would Be Purposeful, Forceful And Immediate; Says If We Have To Act We Wouldn't Relent Until Tariffs Are Removed, Adds Everything Is On The Table

Susquehanna analyst James Friedman maintains Visa (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/V#NYSE">V</a>) with a Positive and raises the price target from $375 to $395.

Price Target

Analyst Ratings

Susquehanna Maintains Positive on Visa, Raises Price Target to $395

Scotiabank analyst Maher Yaghi maintains Rogers Communications (TSX:<a class="ticker" href="https://www.benzinga.com/stock/RCI#TSX">RCI</a>) with a Sector Outperform and lowers the price target from C$64 to C$58.

TSX:RCI

TSX:RCI/B

Scotiabank Maintains Sector Outperform on Rogers Communications, Lowers Price Target to C$58

Susquehanna analyst Bascome Majors maintains United Parcel Service (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UPS#NYSE">UPS</a>) with a Neutral and lowers the price target from $140 to $130.

Susquehanna Maintains Neutral on United Parcel Service, Lowers Price Target to $130

Guidance

ABBV

AbbVie Expects Net Revenues Of About $12.8B For Q1, Adj. Eps Between $2.47 And $2.51

Susquehanna analyst Christopher Rolland maintains STMicroelectronics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STM#NYSE">STM</a>) with a Positive and lowers the price target from $33 to $28.

Susquehanna Maintains Positive on STMicroelectronics, Lowers Price Target to $28

Orrstown Finl Servs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORRF#NASDAQ">ORRF</a>) just disclosed its Q4 earnings on Friday, January 31, 2025 at 07:22 AM.
Here's a brief overview of the earnings report.
<h3>Earnings</h3>
Orrstown Finl Servs missed estimated earnings by -16.0%, reporting an EPS of $0.87 versus an estimate of $1.03.
Revenue was up $24.55 million from the same period last year.
<h3>Performance in Previous Earnings</h3>
The company beat on EPS by $0.19 in the last quarter, resulting in a 3.0% increase share price change the following day.
Here's a look at Orrstown Finl Servs's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.92</td>
<td>0.73</td>
<td>0.73</td>
<td>0.80</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>1.11</td>
<td>0.83</td>
<td>0.88</td>
<td>0.83</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>49.23M</td>
<td>25.97M</td>
<td>25.80M</td>
<td>26.25M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>51.70M</td>
<td>26.10M</td>
<td>26.88M</td>
<td>26.02M</td>
</tr>
</tbody>
</table>

 Listen to the earnings announcement yourself by <a href="">clicking here</a>. 
To track all earnings releases for Orrstown Finl Servs <a href="https://www.benzinga.com/quote/ORRF/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ORRF

Earnings Breakdown: Orrstown Finl Servs Q4

Susquehanna analyst Bascome Majors maintains Schneider National (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNDR#NYSE">SNDR</a>) with a Neutral and raises the price target from $31 to $32.

SNDR

Susquehanna Maintains Neutral on Schneider National, Raises Price Target to $32

AbbVie Exec Says Co Expects Humira Revenue Of $5.6B, With US Sales Of $4B In 2025

Susquehanna analyst James Friedman maintains Mastercard (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MA#NYSE">MA</a>) with a Positive and raises the price target from $605 to $670.

Susquehanna Maintains Positive on Mastercard, Raises Price Target to $670

Scotiabank analyst Patrick Colville maintains Dynatrace (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DT#NYSE">DT</a>) with a Sector Outperform and raises the price target from $62 to $67.

Scotiabank Maintains Sector Outperform on Dynatrace, Raises Price Target to $67

Susquehanna analyst Shyam Patil maintains Check Point Software (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHKP#NASDAQ">CHKP</a>) with a Positive and raises the price target from $215 to $255.

CHKP

Susquehanna Maintains Positive on Check Point Software, Raises Price Target to $255

Morgan Stanley analyst Jeffrey Goldstein maintains Waste Management (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WM#NYSE">WM</a>) with a Equal-Weight and raises the price target from $227 to $235.

Morgan Stanley Maintains Equal-Weight on Waste Management, Raises Price Target to $235

Dow Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOW#NYSE">DOW</a>) reported worse-than-expected fourth-quarter financial <a href="https://in.benzinga.com/25/01/43333833/dow-misses-q4-estimates-as-packaging-segment-struggles-announces-cost-cuts-job-reductions">results on Thursday.</a>
Sales declined 2% year over year to $10.4 billion, missing the consensus of $10.51 billion, on weakness in Packaging &amp; Specialty Plastics segments.
Sequentially, net sales fell 4%, led by seasonal declines in Performance Materials &amp; Coatings. Local prices fell 3% year-over-year and sequentially due to declines in all operating segments.
Operating EBIT declined to $454 million from $559 million a year ago, while the margin contracted by 90 bps to 4.4% for the quarter. Adjusted EPS was $0.00, missing the consensus of $0.24.
Jim Fitterling, chair and chief executive officer, said, "Despite persistently weak macroeconomic conditions, Team Dow delivered our fifth consecutive quarter of year-over-year volume growth, leveraging our cost-advantaged footprint to capture resilient demand for high-value applications."
To navigate the economic downturn, the company expects to reduce 2025 capital expenditures by $300 million-$500 million.
Dow shares fell 6.1% to close at $38.55 on Thursday.
These analysts made changes to their price targets on Dow following earnings announcement.
<ul>
<li>Barclays analyst Michael Leithead maintained Dow with an Equal-Weight rating and lowered the price target from $48 to $44.</li>
<li>Morgan Stanley analyst Vincent Andrews maintained Dow with an Equal-Weight rating and cut the price target from $46 to $43.</li>
</ul>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/01/43335398/wall-streets-most-accurate-analysts-spotlight-on-3-risk-off-stocks-delivering-high-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Spotlight On 3 Risk Off Stocks Delivering High-Dividend Yields</a></li>
</ul>

These Analysts Lower Their Forecasts On Dow After Downbeat Earnings

Morgan Stanley analyst Meta Marshall maintains Viavi Solutions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VIAV#NASDAQ">VIAV</a>) with a Underweight and raises the price target from $9.5 to $10.

VIAV

Morgan Stanley Maintains Underweight on Viavi Solutions, Raises Price Target to $10

Anthony Pompliano, CEO of Professional Capital Management believes multiple countries are buying Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) under the radar and predicts a &#8220;fun 2025&#8221; if that <a href="https://www.benzinga.com/money/will-bitcoin-prices-increase-during-the-trump-presidency">turns out to be the case.</a>
What Happened: In a <a href="https://x.com/APompliano/status/1884683035272249653">post</a> on X on Thursday, Pompliano pointed to recent developments, including the <a href="https://www.benzinga.com/markets/cryptocurrency/25/01/43299857/czech-central-bank-considering-5-bitcoin-reserve">Czech National Bank's proposal</a> to allocate billions to Bitcoin, as a major turning point. 
If implemented, this would mark one of the first instances where a central bank openly integrates BTC into its reserves.
With Bitcoin being relatively uncorrelated to bonds, the proposed 5% allocation is notably higher than the 1-2% typically allocated to alternative assets, making it a compelling diversification play, according to Pompliano.
This move follows a broader trend of nation-state Bitcoin adoption: 
<ul>
<li>El Salvador <a href="https://www.benzinga.com/markets/cryptocurrency/25/01/43336076/el-salvador-changes-bitcoin-law-but-legal-tender-status-remains#:~:text=El%20Salvador%20became%20the%20first,trailblazer%20in%20digital%20currency%20adoption.">continuously accumulating BTC</a> as part of its treasury strategy</li>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42387366/bitcoin-sellers-delight-bhutan-transfers-40m-in-btc-to-qcp-capital">Bhutan holding Bitcoin</a> worth 50% of its GDP through its sovereign investment arm</li>
<li><a href="https://www.benzinga.com/24/12/42677932/russian-firms-adopt-bitcoin-for-global-trade-in-response-to-western-sanctions-should-be-expanded-and-developed-further">Russia exploring BTC mining</a> and international payments amid financial sanctions</li>
<li>Donald Trump signing an executive order to explore a <a href="https://www.benzinga.com/markets/cryptocurrency/25/01/43270841/how-donald-trump-could-make-the-strategic-bitcoin-reserve-a-reality">national digital asset stockpile</a></li>
</ul>
In his latest Pomp Letter, Pompliano argues that Bitcoin operates on an entirely different level compared to traditional investments like the S&amp;P 500, gold,and even Berkshire Hathaway. 
He dubs <a href="https://www.benzinga.com/markets/cryptocurrency/25/01/42815711/bitcoin-is-the-the-grand-daddy-and-outshines-wall-street-anthony-pompliano-says">BTC the &#8220;Grand Daddy&#8221; of assets</a>, continuing to outshine Wall Street.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/25/01/43161311/donald-trump-has-more-than-50-of-net-worth-in-crypto-will-establish-strategic-bitcoin-reserve-anthony-pompliano-predicts">Donald Trump Has &#8216;More Than 50%&#8217; Of Net Worth In Crypto, Will Establish Strategic Bitcoin Reserve, Anthony Pompliano Predicts</a>
What's Next: Pompliano speculates that many countries are quietly accumulating Bitcoin, waiting for the right moment to disclose their holdings to avoid driving up prices prematurely.
If central banks officially enter the Bitcoin market in 2025, it could ignite a massive wave of institutional and retail FOMO, reinforcing the long-held belief that nation-state adoption is inevitable.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42349063/anthony-pompliano-says-countries-are-going-to-fomo-into-buying-bitcoin">Anthony Pompliano Says Countries Are &#8216;Going To FOMO&#8217; Into Buying Bitcoin</a></li>
</ul>
Image: Shutterstock

Anthony Pompliano: Countries Secretly Accumulating Bitcoin, 2025 Could Be 'Fun'

Morgan Stanley analyst Ravi Shanker maintains United Parcel Service (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UPS#NYSE">UPS</a>) with a Underweight and lowers the price target from $100 to $82.

Morgan Stanley Maintains Underweight on United Parcel Service, Lowers Price Target to $82

Looking into the current session, CACI International Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CACI#NYSE">CACI</a>) shares are trading at $383.61, after a 0.79% decrease. Over the past month, the stock decreased by 8.04%, but over the past year, it actually increased by 11.49%. With questionable short-term performance like this, and great long-term performance, long-term shareholders might want to start looking into the company's price-to-earnings ratio. 

<img src="https://www.benzinga.com/files/images/story/2025/1738333909_0.png" alt="Past Year Chart" />

<h3>A Look at CACI International P/E Relative to Its Competitors</h3>
The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current performance against it's past earnings, historical data and aggregate market data for the industry or the indices, such as S&amp;P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also could indicate that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future. 
Compared to the aggregate P/E ratio of the 40.99 in the Professional Services industry, CACI International Inc. has a lower P/E ratio of 18.15. Shareholders might be inclined to think that the stock might perform worse than it's industry peers. It's also possible that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1738333909_1.png" alt="Guage" />

In conclusion, the price-to-earnings ratio is a useful metric for analyzing a company's market performance, but it has its limitations. While a lower P/E can indicate that a company is undervalued, it can also suggest that shareholders do not expect future growth. Additionally, the P/E ratio should not be used in isolation, as other factors such as industry trends and business cycles can also impact a company's stock price. Therefore, investors should use the P/E ratio in conjunction with other financial metrics and qualitative analysis to make informed investment decisions.

CACI

P/E Ratio Insights for CACI International

Williams-Sonoma (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WSM#NYSE">WSM</a>) has outperformed the market over the past 10 years by 6.92% on an annualized basis producing an average annual return of 18.34%. Currently, Williams-Sonoma has a market capitalization of $26.78 billion. 
Buying $100 In WSM: If an investor had bought $100 of WSM stock 10 years ago, it would be worth $538.17 today based on a price of $217.51 for WSM at the time of writing.
<h3>Williams-Sonoma's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738333902_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Comments

CervoMed

CervoMed (CRVO) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga